Stockscreener 앱 받기
11.08
2.12%
-0.235
전일 마감가:
$11.31
열려 있는:
$11.16
하루 거래량:
902.45K
Relative Volume:
0.50
시가총액:
$1.87B
수익:
$68.56M
순이익/손실:
$-437.99M
주가수익비율:
-3.5004
EPS:
-3.1639
순현금흐름:
$-396.61M
1주 성능:
+13.19%
1개월 성능:
+25.08%
6개월 성능:
+21.78%
1년 성능:
+119.64%
1일 변동 폭
$11.03
$11.46
1주일 범위
$9.435
$11.46
52주 변동 폭
$4.75
$11.66
비르 바이오테크 Stock (VIR) Company Profile
명칭
Vir Biotechnology Inc
전화
415-906-4324
주소
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
11.07 | 1.56B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
542.85 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
790.88 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,028.51 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.21 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
206.73 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
비르 바이오테크 Stock (VIR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-09-03 | 개시 | Evercore ISI | Outperform |
| 2025-08-27 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-09-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-03-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-02-21 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-01-27 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | 개시 | SVB Leerink | Outperform |
| 2022-09-09 | 개시 | Morgan Stanley | Underweight |
| 2022-03-03 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-09-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-01-27 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-09-14 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-09-11 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-08-20 | 개시 | Needham | Buy |
| 2020-03-19 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2020-03-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-02-27 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-14 | 개시 | Robert W. Baird | Neutral |
| 2019-11-05 | 개시 | Barclays | Overweight |
| 2019-11-05 | 개시 | Cowen | Outperform |
| 2019-11-05 | 개시 | Goldman | Buy |
| 2019-11-05 | 개시 | JP Morgan | Overweight |
모두보기
비르 바이오테크 주식(VIR)의 최신 뉴스
Vir Biotechnology (NASDAQ: VIR) ex-officer files notice for potential $245K stock sale - Stock Titan
Vir Biotechnology on Track for Record Winning Streak -- Data Talk - Bitget
Vir (VIR) Close and Levels: Adds 1.06% to Close at $9.49 in the Latest Reading; Key Levels: the $9.02 to $9.96 Range Remains in Focus in Latest TradingRevenue Weighted - vinanet.vn
The Bull Case For Vir Biotechnology (VIR) Could Change Following A Sudden Swing To Quarterly Profitability - Sahm
Vir Biotechnology’s Earnings Call Signals Data-Driven Momentum - TipRanks
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership - Stocktwits
Vir Biotechnology (VIR) Climbs 2.67% to $9.24 as Trading Volume Picks UpETH Profile - vinanet.vn
Vir Biotechnology Stock Price Forecast. Should You Buy VIR? - StockInvest.us
Vir Biotechnology, Inc. (VIR) Stock Forecasts - Yahoo Finance
Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript - The Globe and Mail
Vir Biotechnology (VIR) director restructures 16,000-share holding with Alta Partners fund - Stock Titan
Equities Analysts Offer Predictions for VIR Q3 Earnings - marketbeat.com
Vir Biotechnology: Astellas Deal Pushes Cash Above $1 Billion And Extends Runway Into Second Half Of 2028 - Pulse 2.0
Vir Biotechnology (NASDAQ:VIR): What’s Driving Fresh Attention? - Kalkine Media
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits
H.C. Wainwright reiterates Vir Biotechnology stock rating on trial progress By Investing.com - Investing.com Canada
Vir Biotechnology Inc (VIR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vir Biotechnology (VIR) Receives a Buy from Bank of America Securities - The Globe and Mail
What Vir Biotechnology (VIR)'s Profit Swing But Earnings Miss Means For Shareholders - simplywall.st
Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Wall Street Zen - MarketBeat
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $15 to $30 - Moomoo
Vir Biotechnology (VIR): State Street discloses 9.96M-share, 5.9% ownership position - Stock Titan
Understanding Momentum Shifts in (VIR) - Stock Traders Daily
Vir Biotechnology, Inc. Stock 12‑Month Price Target Cut to $21, Implies 140% Upside - TradingView
Vir Biotechnology Inc (VIR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vir Biotechnology, Inc. (VIR) Stock Analysis: Unpacking a 140% Potential Upside for Investors - DirectorsTalk Interviews
Vir Biotechnology, Inc. Stock 12‑Month Price Target Cut to $21.11, Implies 132% Upside - TradingView
Vir Biotechnology, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
VIR Looks 63.2% Undervalued on GF Value™ - GuruFocus
Vir Biotechnology Q2 Earnings Call Highlights - MarketBeat
Vir Biotechnology, Inc. Stock 12‑Month Price Target Cut to $21.33, Implies 134% Upside - TradingView
VIR SWOT Analysis: Financial Resilience Amidst Clinical Challenges Revealed in 10-Q Filing - GuruFocus
Vir Biotechnology Inc (VIR) (Q2 2026) Earnings Call Highlights: - GuruFocus
Vir Biotechnology Inc (VIR) (Q2 2026) Earnings Call Highlights: 88% HDV Cure Rate and a $1B ... - Yahoo Finance
Vir Biotechnology (NASDAQ:VIR) Jumps 10% on Q2 Beat and Astellas Collaboration - ChartMill
VIR Looks 62.9% Undervalued on GF Value™ Despite Unprofitable St - GuruFocus
Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates - Yahoo Finance
Earnings call transcript: Vir Biotechnology jumps on q2 2026 cash and data gains - Investing.com
Vir Biotechnology, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Is Vir Biotechnology Inc (VIR) Undervalued After Q2 Earnings? EP - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS - MarketBeat
Vir Biotechnology Q2 2026 slides: hepatitis delta, oncology gains - Investing.com
Vir Biotechnology (VIR) Releases Q2 2026 Earnings: Revenue and EPS Beat Estimates - Quiver Quantitative
Vir Biotechnology Inc. (VIR) Tops Q2 EPS by 14c - StreetInsider
Vir Biotechnology 2Q 2026: Revenue $238.95M, Net income $80.08M, EPS $0.47— 10-Q Summary - TradingView
Vir Biotechnology (NASDAQ: VIR) swings to profit on $239.3M Astellas deal - Stock Titan
Earnings Flash (VIR) Vir Biotechnology, Inc. Reports Q2 Revenue $238.9M - marketscreener.com
Vir Biotechnology Q2 revenue up, beats estimates on Astellas payment - TradingView
Vir Biotechnology posts $238.9M Q2 revenue, $80.1M net income; $1.01B cash runway into H2 2028 - TradingView
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results - marketscreener.com
비르 바이오테크 (VIR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.38%
자본화:
|
볼륨(24시간):